Proinnovera, a German dermatology contract research organization, has created a subsidiary based in Wilmington, according to a news release.
Proinnovera Inc. opened its U.S. operations in Wilmington on June 1, according to the release. The subsidiary specializes in clinical trial services for studies involving dermatology, immunology, inflammatory skin diseases, skin cancer and pre-cancerous indications, burns, wounds and aesthetics.
According to a Secretary of State corporations division filing, the company's Wilmington address is 1800 Sir Tyler Drive at the Pharmgate building.
Sonja VanWye was named vice president of the company's U.S. clinical operations. According to the release, VanWye will be responsible for general management, team development, contributing to site and vendor selection and expanding the CRO’s U.S. footprint. She previously worked at Novella Clinical, a CRO headquartered in Morrisville, and TKL Research, a clinical research company based in New Jersey, according to her LinkedIn profile.
“I am honored to be guiding our efforts in the expansion of the U.S. footprint for Proinnovera,” said VanWye in the news release. “Adding professionals in the U.S. with deep industry and therapeutic experience along with strong credentials will complement the quality of our current teams and enhance our ability to meet all the needs of our clients.”
In the release, officials stated that the company expanded to Wilmington because clients demonstrated a need for a global CRO that had networks in the U.S.
“We’re seeing the need for global reach of dermatology studies ever increasing,” said Marion Breuer, co-CEO of Proinnovera, in a news release. “We want to meet this need by offering our clients a global presence with deep and responsive local expertise.”
According to the company website, Proinnovera was founded in 1997 by Burkhard Breuer, and is headquartered in Munster, Germany. Its global reach expands to 980 countries and 2,100 employees, and the company has completed 5,700 clinical trials.
Proinnovera Inc. joins other Wilmington-located CROs and pharmaceutical companies, including Pharmaceutical Product Development (PPD), Alcami, Chiltern, PMG Research and Quality Chemical Laboratories, among many others.